Core Insights - Fuhong Hanlin's self-developed PD-1 inhibitor, Hanshuai (Slulizumab), achieved the primary endpoint of event-free survival (EFS) in the Phase III clinical study (ASTRUM-006) for gastric cancer, marking a significant breakthrough in perioperative treatment options [1] - The study demonstrated that Hanshuai combined with chemotherapy significantly improved EFS and achieved a pathological complete response (pCR) rate over three times higher than the control group, with no new safety signals reported [1] Company Focus - Fuhong Hanlin is strategically focused on gastrointestinal tumors, including esophageal, gastric, and colorectal cancers, developing a diversified product portfolio that spans from immunotherapy to targeted drugs [2] - The company aims to leverage its multi-layered innovative therapy matrix and extensive global multi-center clinical trial data to maintain its leading position in the gastrointestinal tumor field [2]
全球首个！复宏汉霖H药胃癌围术期III期达到主要终点 支持提前申报上市